




PCT/GB 2003 / 0 0 3 8 6 6  
Rec'd PCT/PTO  
04 MAR 2005

INVESTOR IN PEOPLE

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 830




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Am. B. Jones*

Dated 26 September 2003

Patents Form 1/77

Patent  
(Rule 1b)



1/77

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



1. Your reference

SMK/LP6092456

06 SEP 2002

09SEP02 E746540-1 002823

2. Patent application number

(The Patent Office will fill in this part)

0220773.6

P01/7700 0.00-0220773.6

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Patents ADP number (if you know it)

07260672001

John Innes Centre  
Norwich Research Park  
Colney Lane  
Norwich  
Norfolk NR4 7UH  
UNITED KINGDOM

If the applicant is a corporate body, give the country/state of its incorporation

GB

4. Title of the invention

Genome Partitioning

5. Name of your agent (if you have one)

MEWBURN ELLIS

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

YORK HOUSE  
23 KINGSWAY  
LONDON  
WC2B 6HP

Patents ADP number (if you know it)

109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request?

(Answer "Yes" if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

YES

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form No

Description 31

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (Please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

6 September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom DR SIMON KREMER 020 7240 4405

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

GENOME PARTITIONINGTECHNICAL FIELD

5 This invention relates generally to nucleic library construction, for example for sequence variation discovery and screening. Particularly, it relates to methods and materials for reproducibly cloning a subset of a sample nucleic acid having reduced  
10 complexity.

BACKGROUND ART

15 Genetic markers are of increasing importance in the genomics and proteomics fields in understanding phenotype, susceptibility to disease, and response to treatments.

Single nucleotide polymorphisms (SNPs) are one of the most abundant and useful markers, and are the subject of investigation in  
20 numerous different organisms, including within the human genome. Methods which have been used in the art have included shotgun sequencing the whole genome or sequencing PCR products (see e.g. Roth (2001) Nature Biotechnology 19: 209-211). Thus shotgun  
25 sequencing of the whole human genome provided a few millions of SNP from five different individuals as a by-products<sup>1</sup> to the main initiative. A more routine method is to design a pair of specific primers for each DNA fragment of interest. After PCR amplification, the fragment can be purified and sequenced. Although these are  
30 widely used methods, their efficiency and throughput are very limited. Moreover, both of them are very costly.

Unfortunately the size of eucaryote genome make it difficult to search or screen for DNA sequence variation between individuals. To address this problem, attempts have been made to reduce the  
35 complexity of the genome to a more manageable scale, and thereby facilitate marker discovery.

AFLP is one method of achieving this. It had been widely used to study DNA polymorphisms and AFLP markers have been mapped in many

species<sup>2</sup>. However, AFLP has not been used for SNP screening because of its technical limits, such as artificial sequence alteration, high proportion of random fragment loss and complexity of the procedure.

5

More recently, a more targeted and collaborative effort had been made to reduce the genome complexity for searching human SNPs.

10

This technology was called the reduced representation shotgun (RRS) strategy and it was adopted for the global human SNP consortium project. RRS reduced the complexity of the genome by about six-fold, which increased the efficiency for finding the SNP. For RRS, the DNA is digested with a restriction enzyme. Based on the distribution of the fragments at different sizes, a subset of the fragments can be cut out from an electrophoresis gel so that the subset only contains the fragments with a particular size interval. The isolated fragments are subsequently be cloned into a library for random sequencing<sup>3</sup>. (see Roth (2001) Nature Biotechnology 19: 209-211).

20

EP 1001037 (Whitehead Biomedical Inst., US) describes such an RRS strategy. A nucleic acid-containing sample to be assessed is treated to fractionate it into fragments selected in a sequence-dependent manner, a subset of which is selected on the basis of size.

25

The drawback of this method is that it can only reduce the genome complexity by a small scale.

30

Thus it can be seen that alternative methods of reproducibly reducing the complexity of nucleic acid samples to a controllable scale e.g. for marker discovery, would provide a contribution to the art.

### 35 DISCLOSURE OF THE INVENTION

The present inventors have developed methods to reduce the complexity of a sample of nucleic acid (e.g. genomic or cDNA library) in large, flexible and controllable scales by dividing the

genome or a collection of cDNA into smaller subsets. Briefly, the method uses multiple restriction enzymes to cut the DNA into a collection of restriction fragments. Based on the unique restriction ends of the fragments, they are then divided into  
5 different groups or "layers". A layer, or a combination of layers, is then cloned at a specific restriction site such that the resulting library only contains the desired subset or partition of the total sample. This permits the reduction of e.g. a genomic library's complexity more than a thousand-fold. By treating each  
10 sample (or pooled samples) in this way, a highly consistent sub-set of corresponding fragments is generated in each case. Thus the method has particular utility for sequence variation discovery or screening through direct sequencing. Additionally it can be utilised within automated systems to provide high-throughput  
15 screening.

Thus in a first aspect there is provided a method for producing a nucleic acid library, which library contains a plurality of different nucleic acid fragments, the combination of said fragments  
20 being a representative partition of the entirety of a sample nucleic acid, the method comprising:

- (i) digesting the sample nucleic acid with a plurality of different restriction enzymes to generate a plurality of different layers of fragments,  
25 wherein each layer is a group of fragments having a unique combination of restriction ends,  
and wherein the combination of layers represents the entirety of the sample nucleic acid,
- (ii) optionally purifying said fragments,
- 30 (iii) selecting a desired sub-set of layers according to the unique restriction ends of said layers,
- (iv) ligating said sub-set of layers into vectors adapted to receive it,
- (v) transforming host cells with the vectors
- 35 (vi) culturing said host cells to provide said library containing said partition of the sample nucleic acid.

Thus the method provides a reproducible method of reducing the complexity of the sample. By selection of the appropriate numbers

of restriction enzymes, the type of restriction enzymes, and the sub-set of layers ligated into said vectors, a partition with at least 10, 100, or 1000-fold reduced complexity compared to the sample nucleic acid can be generated.

5

In preferred embodiments, the method is performed (including, optionally, purification to remove short sequences e.g. less than 100 bps) such that the sub-set of layers ligated into said vectors provides a library with fragments with a size range of 100-2000 bps.

10

The number of restriction enzymes, the type of restriction enzymes, and the sub-set of layers ligated into said vectors are selected in accordance with the equations set out hereinafter.

15

#### *Choice of nucleic acid sample*

Nucleic acid for use in the present invention may include cDNA, RNA and genomic DNA. It may be provided in amplified form. RNA may be provided as cDNA.

20

Generally speaking, for cDNA samples, the total size of the cDNA pool will be smaller than a genome. Therefore, fewer enzymes will be used and pilot tests (see below) can be used to optimise the design.

25

The sample may represent all or part of a particular source of origin e.g. may have been enriched.

Nucleic acids for use in the present invention may be provided isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or free or substantially free of other nucleic acids of the species of origin. Where used herein, the term "isolated" encompasses all of these possibilities.

30

#### *Choice of restriction enzymes*

In preferred embodiments, between 3 and 6 restriction enzymes will be used e.g. equal to, or at least, 3, 4, 5 or 6.

Preferably, the restriction enzymes are selected from four-, six- or eight- base-cutters.

5 Preferably, one or two six-base-cutters (which cut relatively rarely) are used as cloning-end-generators to create the cloning ends for the layer(s) which are selected for cloning. The other restriction enzymes are four-base-cutters (which cut relatively more frequently) and which are used, in effect, as fragment-cutters  
10 to destroy some or most of the fragments which could otherwise be cloned into the chosen vector. These enzymes therefore serve to reduce the size of the selected layer(s). A combination of four- and six-base cutters as fragment cutters may be useful to 'hone' the size of the partition.

15 Preferred restriction enzymes are selected from any of those given in Table 1. Eight-base cutters include SfiI and NotI. More preferably the enzymes HpaII, AluI, DraI, and PstI are used (PstI being used to generate cloning ends).

20 However those skilled in the art will appreciate that other combinations of enzymes may be selected as appropriate to the specific application in hand - for instances when all or part of a reference sequence for a sample is known, the enzymes will be  
25 selected such as to have a target frequency appropriate to the size of the partition which it is wished to generate. Likewise if it is desired to investigate a particular region of the sample, the enzymes will be selected such as to achieve this.

30 Preferably the plurality of enzymes are used simultaneously, and are selected such as to be active under comparable conditions to permit this. Optimum conditions for commercially available restriction enzyme are available from the manufacturers.

35 Restriction by one enzyme may be partial. In such cases it is preferred that the group of fragments in the selected layer have restriction ends created by said partial digestion.

*Choice of layers*



In preferred embodiments, the selected sub-set of layers consists of one layer or two layers

- 5 The following represent various preferred embodiments of the invention:

*Design of partitions for samples with unknown sequence and size*

- 10 In some embodiments it may be required to generate a partition having a desired number of unique fragments where no reference sequence is available in a genome of unknown size. In this case the present invention may incorporate the performance of a 'pilot test' to confirm the validity of the partition design, and  
15 optionally to refine it:

A pilot test may be used to measure the size or complexity (number of unique sequences) of a particularly designed partition. It will also provide information about original genome size and restriction  
20 site frequencies. The principle is as follows: when sequencing a library (e.g. a partition) having a given number of colonies, there will be a chance for a particular sequence to be sequenced more than once. This is called sequence redundancy of shotgun sequencing strategy. The more colonies sequenced the more redundancy. The  
25 smaller (or less complex) the library, the more redundancy. Thus assessment of sequence redundancy provides information about the size of the partition.

The function is described in this formula:

30 
$$F = n(n-1) \sum_i [n_i(n_i-1)]^{-1} \pm s..$$

Wherein:

- F is the size or complexity of the partition  
35 n is the total number of good sequences obtained by sequencing  
ni is the number of times that the 'i'th sequence has been sequenced, when sequences are aligned after sequencing,  
s is the standard deviation.

Thus, for example, 500 colonies may be selected from a partition and sequenced. This should give more than 400 good quality sequences.

- 5 Using these sequences, the complexity of the partition,  $F$ , can be calculated. Additionally, the deviation constant for restriction enzymes in the genome can be extrapolated from the sequence results permitting a honing of the partition design.
- 10 Thus the method may include performing the method of the invention as described above using parameters which are likely to produce an acceptable result for a wide spread of genome sizes from different species, for example by performing a digestion of 5µg genomic DNA using a 6nt cutter (e.g. PstI) as the cloning site enzyme and three  
15 4nt cutters (e.g. HpaII, AluI and DraI). The partition may be cloned into pZErO at PstI site with presence of suitable enhancing linkers (linkers for HpaII, AluI and DraI).

The following steps are then performed:

- 20 (vii) sequencing the fragments in a fraction of the colonies (host cells) in said library,  
(viii) calculating the size of the library (i.e. partition) using formula  $F = n(n-1) \sum_i [n_i(n_i-1)]^{-1} \pm s$ .

- 25 If the partition size is appropriate it can be accepted.

If not (for example it is too small or too big) then the following further steps, in any appropriate order, may be performed:

- 30 (ix) providing the restriction site frequency ( $f_i$ ) of the enzymes used in the partition, for example based on sequences obtained at step(vii),  
(x) calculating the genome size  $G$  using the formula:

$$N_{x1-x2} = GP_1^2 \sum_{k=x1}^{k=x2} \prod_{i=1}^i (1-P_i)^k$$

wherein:

$N_{x1-x2}$  is the number of fragments with length between  $x1$  and  $x2$

(which is F above).

k is fragment length

x1 and x2 are upper and lower limits of the size range of the fragments in the library (these may be assumed as 100bp and 2000bp, as described above, or can be verified by the sequence obtained)

$P_i$  is the probability of having a restriction site at any given base for the 'i'th enzyme,

(xi) providing a restriction site frequency ( $f_i$ ) for enzymes not used in the partition, for example based on sequences obtained at step(vii) (this can also be expressed as  $P_i$ ),

(xii) selecting further restriction enzymes on the basis of restriction site frequency ( $f_i$ ) to generate a desired size of partition using the formula:

$$N_{x1-x2} = GP_1^2 \sum_{k=x1}^{k=x2} \prod_{i=1}^i (1-P_i)^k$$

(xiii) producing a further nucleic library in accordance with steps (i)-(vi) using at least one of these further restriction enzymes.

A corresponding approach may be used with cDNA from an unknown tissue from an unknown species. In such case the lower complexity (compared with a genome) suggests that PstI as the cloning site restriction enzyme, and HpaII as the fragment cutter, may be an appropriate starting point.

#### *Design of partitions for samples of known size and unknown sequence*

Where the approximate genome size (G) is known, in choosing the enzymes to be used in step (i), the restriction site frequency may be assumed to be randomly distributed i.e. the  $v = 1$ , wherein, v is the deviation constant in the formula  $P=v/256$  for four base cutter and  $P=v/1096$  for six base cutter.

The enzymes to produce a desired partition size are thus selected on the basis of the formula:

$$N_{x1 \sim x2} = GP_1^2 \sum_{k=x1}^{k=x2} \prod_{i=1}^i (1 - P_i)^k,$$

More specifically the formula:

$$5 \quad N' = 4^{-12} v' G \sum_{k=x1}^{k=x2} \left[ (1 - 1/4^4)^{nk} (1 - 1/4^6)^{(1+m)k} \right]$$

wherein:

$k$  is fragment length (and  $x1$  and  $x2$  are upper and lower limits)

10  $G$  is the size of the genome

$n$  is the number of extra 4 nt cutters

$m$  is the number of extra 6 nt cutters

is used to select an appropriate combination of 4nt and 6nt  
15 cutters.

This can be verified as described above in steps (vii)-(xiii) if required.

20 A corresponding approach may be used with cDNA from tissues or species in which the complexity is known or can be estimated, either directly or by comparison with other species.

#### *Samples with known sequence*

25

One or more reference sequences corresponding to the sample nucleic acid may be known. It will be understood that the sample nucleic acid sequence (inasmuch as it derives from a different source from the reference) is likely to include sequence variation with respect  
30 to any reference and indeed this variation between corresponding sequences underlies certain embodiments of the present invention: Nevertheless, since such variations are by definition rare, the reference sequence can be used to calculate restriction site frequency for restriction enzymes which it may be desired to use in  
35 the methods described herein.

When the sequence is known, the restriction site frequency of each enzyme can be provided, and the formula:

$$N_{x1 \sim x2} = GP_1^2 \sum_{k=x1}^{k=x2} \prod_{l=1}^l (1 - P_l)^k$$

can be used to select the enzymes to produce a desired partition size,

Where a reference sequence is known, a set of restriction enzyme can be based on the restriction map of the desired genes and other sequences so as to select them in particular, while still having an appropriately sized partition.

Some particular practical aspects of the invention will now be discussed in more detail:

#### *Purification*

In preferred embodiments the fragments are purified at step (ii).

As described in the Examples hereinafter, fragments may be purified in a conventional manner. In examples herein, the restriction reaction was passed through a column containing resins (QIAQuick PCR purification kit, QiaGen), which can effectively adsorb DNA molecules larger than 100bp. After washing with 70% ethanol, the DNA fragments were eluted into 30~50µl water. An alternative second method used the BioRad Clean-A-Gene kit. The third method was to purify the fragments by running 1% agarose gel and recovering the DNA by using Promega gel recovery kit. For the third method, extra DNA should be used, for example, 10 microgram for rice and pearl millet, 20 microgram for human and wheat.

Preferred purification techniques will be such as to remove fragments of less than 100 bases.

#### *Enrichment of sample*

Where a corresponding reference sequence is known, an enrichment

strategy may be adopted, so that a particular region or gene may be treated. For example, when a particular set of fragments are required to be enclosed, restriction enzymes may be chosen through a restriction map of the reference sequence(s). Moreover, if a particular set of genes are needed to be studied, from the reference sequence, a set of oligos (16-60 bases preferably 20-50 bases) could be designed to enrich the genes e.g. via a hybridization method using magnetic beads with biotin-labelled oligonucleotides attached on them (see e.g. Edwards KJ, Barker JHA, Daly A, Jones C, Karp A (1996) Microsatellite libraries enriched for several microsatellite sequences in plants. *BioTechniques* 20:758-760). This technique may be particularly useful when dealing with repetitive DNA.

Once the sample is enriched, it may be preferred to use pilot tests to confirm the size of the total DNA pool.

#### *Enhancement linkers*

In preferred embodiments, enhancement linkers are added prior or during step (iv) such that only the desired sub-set of layers being included in said library. The linkers prevent fragments with compatible restriction ends combining to form artifacts.

Such linkers (which may be provided as a pair of oligonucleotides) comprise:

- (i) a core sequence, which is selected such that it does not contain a restriction site and does not have a high probability of hybridizing to target sequence,
- (ii) a portion that matches the appropriate restricted-end
- (iii) additional sequence to prevent the linkers annealing e.g. an overhang.

The enhancement linkers are not used for the cloning site restriction enzyme(s).

Preferred linkers are any of those given in Table 1.

#### *Cloning and ligation*

The terms "cloning" and "ligation" and so on are used herein because they will be well understood by those skilled in the art, and can be performed by standard techniques. Those skilled in the art are well able to clone selected fragments into libraries - see, for example, *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et al, 1989, Cold Spring Harbor Laboratory Press or *Current Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992 (or later editions of these works) both of which are specifically incorporated herein by reference. Generally speaking a typical protocol can be achieved by exposing a vector restricted with the appropriate enzymes to the selected layers such as to ligate or otherwise incorporate the heterologous nucleic acid fragments into the vector at the appropriate cloning site; exposing the ligation product (recombinant vector) to host cells under conditions whereby the vector is taken up by the cells such as to generate a population of host cells containing the vector; exposing the population of cells to a propagation medium comprising a selection agent whereby transformed host cells which contain vector incorporating the nucleic acid insert are selectively grown or propagated in the medium.

Where desired, one or more pairs of "adaptor" oligonucleotides may be used to bridge the cloning ends of the DNA fragments of interest (i.e. from the layer(s) in the desired sub-set) and the cloning site of the vector(s). The adaptor sequences have appropriate restriction site sequences (fragment and vector) at each end and a core sequence in the middle. An example core sequence is 5-CGTAGACGATGCGTGAGAC-3.

In such cases, PCR amplification may optionally be used to enrich the fragments of interest and increase the amount of DNA by using the adaptor sequence as PCR primer. This may be advantageous where the quantity of fragments is relatively low.

Thus, prior to step (iv), the method may optionally include the step of ligating adaptor oligonucleotides to all or part (e.g. generally one or both layers, if two layers are selected) of the

selected sub-set of fragments in order to facilitate their ligation into vectors adapted to receive them.

The adaptor sequences may optionally incorporate extra restriction sites.

*Use for discovery of sequence variation*

As described in more detail below, the sample may comprise  
10 corresponding nucleic acid from several (e.g. two or more)  
different sources. This permits equivalent partitions to be  
compared e.g. for the discovery of sequence variation:

The methods described herein may be used to identify any type of  
15 marker e.g. microsatellites, minisatellites etc. Preferably the  
markers are SNPs.

The size of the partition sequences will be chosen to be  
appropriate to the number and nature of markers which it is desired  
20 to look for. Thus, for example, if 'S' different SNPs are required,  
it may be appropriate to ensure that there are at least that many  
different unique sequences in the partition (more preferably twice  
that many) representing a total length of  $S \times 1000$  bases.

25 Markers can be investigated which are appropriate to the samples.  
For example, the nucleic acid-containing sample can be pooled from  
individuals who share a particular trait (e.g. an undesirable  
trait, such as a particular disorder, or a desirable trait, such as  
resistance to a particular disorder). Sequences can be taken from  
30 different species, varieties or populations such as to provide  
markers for plant-breeding, or phylogenetic studies etc. Preferred  
target genomes (or cDNA sources) include Human, Arabidopsis, wheat,  
rice, millet and soybean genomes.

35 Thus the invention provides a method for identifying a limited  
population of markers in a sample nucleic acid, which method  
comprises:

(a) providing sample nucleic acid from at least 2 different  
sources,



- (b) providing a representative partition of the sample nucleic acid in accordance with the methods described herein,  
(c) identifying differences within corresponding sequences from said different sources contained within the library.

5 The nucleic acid from different sources may be pooled. However it may also be analysed on separate occasions since the methods of the invention produce a partition of fixed size and fixed content in a reproducible manner.

10 Generally the corresponding sequences from the different sources within the partition are sequenced to identify the differences. Such sequence data is obtained by sequencing the library e.g. to 3-5 times coverage. If desired the actual size of partition can be  
15 calculated as described herein.

The term "corresponding to" in terms of sequence comparisons herein (whether with a known reference, or between different source nucleic acids in a sample) refers to sequences derived from  
20 equivalent loci or genes from two different genomes (e.g. the sequences may be orthologues, homologues, alleles etc.) but which may therefore include differences between them (e.g. by way of mutation, polymorphism, or other sequence variation which gives rise to nucleic acid "markers").

25 Corresponding sequences will generally be at least 80% identical, most preferably at least about 90%, 95%, 96%, 97%, 98% or 99% identical. Identity is established by comparison of the full length of the sequences (or the shorter of the sequences). Thus  
30 alignment of different sequencing results, and assessment of the degree of identity between them, can be used to confirm that sequences are indeed corresponding ones, and hence that sequence differences between them represent potential markers. For markers which are candidate single nucleotide polymorphisms, the frequency  
35 should preferably not exceed 1% of the total number of bases in the shorter of the two sequences - sequences which meet these criteria may be selected as corresponding. Whether sequences are indeed corresponding sequences showing intergenomic or inter-gene variation, rather than e.g. multiple copies in a single genome or

individual, can be verified if desired by conventional methods familiar to those skilled in the art of SNP identification. For example, intergenome or inter-gene-copy variation is generally larger than the allelic variation so that a phylogenetic tree of the sequences in an alignment based on sequence similarity may distinguish the two types of variation. If required, SNP candidates can be validated by genotyping and genetic mapping - if the marker segregates and can be mapped to a chromosomal location, it would normally be recognized as true allelic variation.

#### *Use in genotyping*

Many uses of SNPs require: (i) the SNP's map position in the human genome, and (ii) a genotyping assay for scoring the locus in association studies.

Methods for assessment of polymorphisms are reviewed by Schafer and Hawkins, (Nature Biotechnology (1998) 16, 33-39, and references referred to therein) and include: allele specific oligonucleotide probing, amplification using PCR, denaturing gradient gel electrophoresis, RNase cleavage, chemical cleavage of mismatch, T4 endonuclease VII cleavage, multiphoton detection, cleavage fragment length polymorphism, *E.coli* mismatch repair enzymes, denaturing high performance liquid chromatography, (MALDI-TOF) mass spectrometry, analysing the melting characteristics for double stranded DNA fragments as described by Akey et al (2001) Biotechniques 30; 358-367.

The assessment of polymorphisms may be carried out on a DNA microchip. One example of such a microchip system may involve the synthesis of microarrays of oligonucleotides on a glass support. Fluorescently - labelled PCR products may then be hybridised to the oligonucleotide array and sequence specific hybridisation may be detected by scanning confocal microscopy and analysed automatically (see Marshall & Hodgson (1998) Nature Biotechnology 16: 27-31, for a review).

Thus the invention also provides for a method for making a genotyping microchip for use in assaying a limited population of

polymorphisms within a sample (see, e.g., U.S. Pat. Nos. 5,861,242 and 5,837,832).

As with other reduced representation approaches, the present invention can facilitate efficient genotyping. Once a set of polymorphisms is isolated, probes or primers for detecting those polymorphisms can be incorporated into such a chip. When it is desirable to assay an individual for the polymorphisms in the set, nucleic acid is isolated from that individual, and it can be partitioned with the same methods that were used to isolate the original set of polymorphisms.

However, this invention is more flexible than the other reduced representation approaches because it can greatly and flexibly reduce the size of a partition e.g. to as small as one containing 500 unique fragments.

For example, if one wishes to genotype a new sample for 10,000, or 1000 or 100 SNPs isolated from a specific partition, one could restriction-digest the sample; isolate an appropriate partition; and amplify by PCR using primers complementary to a generic linker. The resulting amplification products could be hybridized to an appropriate 'genotyping array'. Such methods allow the user to concentrate study on only a limited portion of the entire spectrum of the available polymorphisms. By examining only a limited portion of the genome, this method has the added benefit of reducing cross-reactivity between unrelated genetic sites.

#### *Use for investigation of methylation sensitivity*

For methylation sensitivity studies, methylation sensitive and non-sensitive restriction enzymes may be used separately so that the methylation distribution patterns could be revealed by comparing the two.

#### *Computer-implemented embodiments*

In a further aspect of the present invention, some or all of the steps of the methods described above may be performed by a digital

computer, in particular steps in designing appropriate genome partitions based on reference sequence restriction maps and/or equations as described above. Although this could be done using commercially available sequence analysis software and sequence databases, in preferred embodiments a bespoke system directly provides the choice of enzymes to use.

Thus the invention provides an automated computer system, comprising a combination of hardware and software; that can rapidly determine optimised partitions based on a reference sequence, a desired size, and optionally desired region within the sequence.

Preferably, these aspects of the invention are implemented in computer programs executing on a programmable computer comprising a processor, a data storage system (including volatile and non-volatile memory and/or storage elements), at least one input device, and at least one output device. Data input through one or more input devices for temporary or permanent storage in the data storage system includes sequences. Program code is applied to the input data to perform the functions described above and generate output information. The output information is applied to one or more output devices, in known fashion.

The program code will include analysis of some or all of the functions described above, and will include the ability to input a reference sequence, and preferences regarding partition size and optionally preferred regions to include in the partition. The program code will also be able to reference (e.g. from a look-up table) restriction site target sequences for different 4 and 6nt cutters.

The automated system can be implemented through a variety of combinations of computer hardware and software. In one implementation, the computer hardware is a high-speed multi-processor computer running a well-known operating system, such as UNIX. In other embodiments personal computers using single or multiple microprocessors might also function within the parameters of the present invention.

Each such computer program is preferably stored on a storage media or device (e.g., ROM or magnetic diskette) readable by a general or special purpose programmable computer, for configuring and operating the computer when the storage media or device is read by the computer to perform the procedures described herein. The inventive system may also be considered to be implemented as a computer-readable storage medium, configured with a computer program, where the storage medium so configured causes a computer to operate in a specific and predefined manner to perform the functions described herein.

The invention will now be further described with reference to the following non-limiting Figures and Examples. Other embodiments of the invention will occur to those skilled in the art in the light of these.

#### Example 1 - methods for determining size of layers and partitions

##### *Relationship between Enzymes and Layers*

When DNA is digested with more than one restriction enzymes, the DNA fragments can be classified into groups based on the restriction ends produced specifically by the restriction enzymes.

When  $N$  different enzymes are used, the maximum number of groups of DNA fragments generated, which are called "layers" herein, is:

$$L = N + (N^2 - N) / 2$$

Each layer of DNA fragments can be specifically cloned into a cloning vector at the corresponding restriction site. The specificity is determined by the cloning site, which only matches the restriction fragment ends of the chosen layers.

##### *Combinations of Layers*

In principle, any combination of the layers can be cloned into a library. The sub-set or combination of layers cloned is termed a "partition" herein. The number of possible partitions will be:

$$P = C_L^1 + C_L^2 \dots + C_L^{L-1}.$$

For example, when five different enzymes were used, there should be up to 15 layers and 32766 partitions. In practice, it is preferred to use only a partition containing one or two layers for library construction. Thus, five enzymes could provide 15 or 225 partitions. Given that more than a hundred of restriction enzymes are available on the market, the number of possible partition of a genome is huge.

#### *Estimating number and size of fragments per layer*

The size of a layer depends on the number and the types of enzymes used.

For a given cloning site generated by a 6nt cutter,  
Total number of fragments = total number of restriction sites =  $\frac{vG}{4^6}$ .

(G stands for genome size in base pairs).

(v is the frequency deviation for each particular enzyme in a particular genome, and may be assumed to be 1 unless known or established to be otherwise).

The possibility of a restriction fragment with length k is  $(1-1/4^6)^k$ .

The possibility of a fragment with length of k is

$$(1-1/4^6)^k - (1-1/4^6)^{k+1}$$

The number of fragments with length between x1 and x2 is

$$N = 4^{-6} vG [(1-1/4^6)^{x1} - (1-1/4^6)^{x2}].$$

With an extra 4nt cutter, the number of fragments per layer will be reduced because a given fragment could be cut internally, to generate fragments with different combinations of restriction ends, and hence no long within the original layer. Thus the fragments per

layer will be reduced to:  $N' = 4^{-12} v' G \sum_{x1}^{x2} [(1-1/4^4)^k (1-1/4^6)^k]$ .

With two extra 4nt cutters,  $N' = 4^{-12} v' G \sum_{x1}^{x2} [(1-1/4^4)^{2k} (1-1/4^6)^k]$ .

With three extra 4nt cutters,  $N' = 4^{-12} v' G \sum_{x1}^{x2} [(1-1/4^4)^{3k} (1-1/4^6)^k]$ .

With n extra 4nt cutters,  $N' = 4^{-12} v' G \sum_{x1}^{x2} [(1-1/4^4)^{nk} (1-1/4^6)^k]$ .

5

With an extra 6nt cutter, the number of fragments will be reduced to  $N' = 4^{-12} v' G \sum_{x1}^{x2} [(1-1/4^6)^{2k}]$ .

With two extra 6nt cutters,  $N' = 4^{-12} v' G \sum_{x1}^{x2} [(1-1/4^6)^{3k}]$ .

10 If one 6nt cutter is used for cloning site, a 4nt extra cutter and 'm' 6nt extra cutters are used, the number of fragments will be

$N' = 4^{-12} v' G \sum_{x1}^{x2} [(1-1/4^4)^{nk} (1-1/4^6)^{(1+m)k}]$ . Herein  $v'$  is a combined frequency

deviation so that this formula is preferred to be used only when  $v'$  is assumed to be one or when pilot test is used to verify the partition design.

15

In general, the number of fragments with length between  $x1$  and  $x2$

(in base pairs) is  $N_{x1-x2} = GP_1^2 \sum_{k=x1}^{x2} \prod_{i=1}^i (1-P_i)^k$ , in which  $P_i$  is the

possibility to have a restriction site at any base pair for the 'i'th enzyme used and  $P_1$  represents that for the enzyme of the

20 cloning site.

It should be noted that when a partition is based on fragments having two different restriction ends, the number of matching fragments remains the same. Although the number of total fragments is doubled with two enzymes, the chance of having two different ends is 50%. Therefore, the size of a partition with one cloning end is the same as that with combination of two different cloning ends if other restriction enzymes (fragment cutters, the enzymes which do not match the cloning site) are the same. Thus for the

25

purposes of calculation, the two restriction enzymes for the cloning site may be counted as one enzyme, with the  $P_1$  taken as the mean of that of the two enzymes.

- 5 In preferred embodiments, most cloned fragments will fall between 100 and 2000 base pairs (and hence  $x_1$  and  $x_2$  may be assumed as 100 bp and 2000 bp). This is because smaller fragments, which are not informative, may be removed by purification techniques. Additionally, the selected restriction endonuclease(s) will  
 10 generally cleave the sample nucleic acid molecule at least approximately every 2000 bases - Thus larger fragments will be comparatively rare.

#### *Testing the number of unique fragments - "pilot testing"*

15

Since the frequency of a given restriction site varies greatly from enzyme to enzyme and from genome to genome, the frequency of the enzymes and the actual size of designed partitions needs to be tested unless it is known from a pre-existing sequence.

20

- To evaluate the number of unique fragments in a partition. After the library of a partition is constructed in accordance with the above, randomly pick and sequence 500 well-separated colonies. Assemble them so that the same sequences will be piled in  
 25 alignments. Each alignment of a sequence may be termed a "contig" or "clique". The number of unique fragments in the partition should be  $F = n(n-1) \sum_i [n_i(n_i-1)]^{-1} \pm s$ , in which  $n$  is the total number of sequence and  $n_i$  is the number of the sequences in the  $i$ th cliques. When the number of sequences is big enough, the standard  
 30 error  $s$  could be neglected.

#### Example 2 - Use of a partition to find DNA sequence variation

##### *Partition strategy*

35

Clearly, the larger the partition, the more sequence reactions are needed to get sequence pair-wise comparison. It is therefore preferred to keep the size of the partition to the minimum likely to encompass the number of sequence variations which it is desired



to identify.

For example, when if five hundreds SNPs are required for a population or a panel of varieties, the partition should provide more than five hundreds unique sequences (ideally about 1000). Random sequencing should preferably cover the library 3-5 times - more than 10-times should not be necessary.

The number and types of restriction enzymes should be decided based on the formulae described above. When the genome sequence is available, the restriction site frequency can be checked and a particular design to cover certain genomic regions or genes can be performed using a known or bespoke programs. Sequence enrichment strategy can also be considered at that stage.

For a new species and a particular set of enzymes, a pilot test is carried out to confirm the expected size of the partition is valid in respect of that genome. For cDNA, a pilot test may be required in each case to hone the partitioning.

#### *Sample preparation*

This can be done in conventional manner. For e.g. rice DNA, at least two microgram is preferred. For the human genome, more than five microgram DNA is recommended for normal genome partitioning without gel-based purification.

#### *Restriction digestion*

Restriction digestion can be performed in one cocktail. However, if the enzymes are optimal in different conditions, two or even three stages of reaction should be carried out.

Partial digestion can be used as a special way to enlarge a partition. Normally, partial digestion only performed on one enzyme, which generates the cloning ends.

#### *Use of Enhancing Linkers*

For ligation, enhancing linkers can be designed to avoid chimerical sequences and restoring the undesired restriction site during ligation. In the Examples herein, each linker consists of two oligos. The core sequence were 5'-TTGGCGTTTAC-3' and 3'-CCGCAAATG-5'.

In order to define the core sequence, a randomly generated short sequences were Blast searched against all sequences from different species in EMBLE database. 5'-GGCGTTTAC-3' was selected on the basis that it had the least hits, and it did not contain a restriction site.

One end of the linker has a hangover 'TT' so that no linkage can be made at this end. The other end has a sticky end with added nucleotides, which matches the restriction ends - this can be linked to the genomic DNA fragments with undesired restriction ends. Because of the competition of these linkers, DNA fragments with the same restriction site as the linkers will not link to each other to create "false" fragments within given layers.

Thus for each used restriction enzyme (except that for cloning site) a corresponding enhancing linker should be added into the ligation reaction. In preferred embodiments the final concentration of each oligo should be 0.1 $\mu$ M. This is conveniently achieved using a stock solution of each oligo (1mM) (which can be stored for use e.g. at -20°C. Before ligation, a 'cocktail' of these oligos is made to contain each necessary oligo with the concentration of 10 $\mu$ M and 1 $\mu$ l of the cocktail should be added in the 100 $\mu$ l ligation reaction.

Preferred enhancing linkers are listed in Table 1 hereinafter. The restriction endonuclease in the list is recommended for genome partitioning.

### Cloning

This can be done in conventional manner. Zero Background vector from Invitrogen was used. Ligation, transformation, colonies picking, miniprep and sequencing were performed using routine DNA

library construction protocols.

Compatibility with Two automated systems (Qiagen Robots 3000 and 8000 with QIAprep 96 Turbo BioRobot Kit) was demonstrated showing the utility of the invention in high-throughput screening.

### Example 3 - SNP discovery in rice

Rice is a model plant for cereals. DNA sequences are widely available for rice subspecies, Indica and Japonica. The rice genome is about 400 million base pairs and has been shot-gun sequenced independently by several groups, while at least one other group (Japanese National Rice Genome Project) is using a BAC strategy. Currently, sequences from Huada<sup>4</sup> and RGP<sup>5</sup> are publicly available for Indica and Japonica respectively.

Genomic DNA was isolated from 20 rice varieties and equally pooled into one sample (Table 2 below).

Ten µg of the pooled DNA was digested with 0.5 µl of HpaII, AluI, DraI and PstI each in a cocktail with GIB buffer 8. The total volume of reaction was 100µl and it was incubated at 37 °C for 12 hours overnight.

The digested DNA was purified using QIAQuick PCR purification kit, QiaGen. The purified DNA was eluted in 20 µl water and subsequently 5µl of the purified DNA fragments were used in a 10µl ligation reaction. Six oligos (as three enhancing linkers for HpaII, AluI and DraI) were added into the reaction. They were 5'-TTGGCGTTTAC-3', 5'-CGGTAAACGCC-3', 5'-TTGGCGTTTAC-3', 5'-GTAAACGCC-3', 5'-TTGGCGTTTAC-3', 5'-AATTGTAAACGCC-3' (see Table 1). The final concentration of each oligo was 0.1µM. One µl of ligase was used and 0.2µg pZero vector (InvitroGen) digested with PstI was added. The reaction was at 15°C for 30 minutes and then kept at -20°C for subsequent transformation.

The one-shot competent cell (InvitroGen) was used for transformation of the E. coli. Kanamycin was used as selection antibiotic. After overnight culture on LB medium agar plate,

approximately 600 colonies were picked up. The colonies were cultured in 1.5ml LB medium and the plasmid DNA was isolated using QuiaGen miniprep kit. Thirty of the plasmid DNA was run on agarose gel to see the size of inserts. Out of the thirty samples, the insert size ranged from 200 to 3000 bp, with average of 800bp. The DNA was sequenced using flourecent-capillary method on ABI 3700 (sequence service was provided by John Innes Centre).

The sequences were processed with PreGap4 to cut away the poor sequence and vector sequence. The sequence with good quality (pregap4 default threshold was used for quality control) can be assembled into contigs using Gap4.

About 400 pairwise comparisons were found (Table 3), from which 278 SNP candidates were identified.

**Table 3 Number of sequences and SNP candidates**

No. of sequences in each contig	No. of Contig	No. of sequences in each contig type	No. of SNP candidates
1	212	212	-
2	121	242	222
3	8	24	46
4	2	8	6
6	1	6	0
8	1	8	4
Total	345	500	278

Using the formula:  $F = n(n-1) \sum_i [n_i(n_i-1)]^{-1} \pm s$ , the size of the partition was estimated as containing 624 unique colonies (the standard error was ignored as being insignificant) (Table 4).

The average size of the colonies was 800bp. Since rice genome is 400 million bp and the size of library was (624 x 800)bp, the genome partition was about 1/800 of the whole genome. In another word, this genome partitioning design reduced the complexity of the library by 800 times.

#### Example 4 - SNP discovery in Pearl millet

Pearl millet (Table 4) was tested using the procedure set out in Example 3. The total number of sequences was 607 from about 800 colonies. The result showed that a partition containing about 2000 colonies were constructed.

Since the size of pearl millet genome is not known accurately, the actual reduction in complexity of the genome was not determined, nor has the total number of SNPs been calculated.

Table 4 Pearl millet varieties pooled for genome partitioning experiment

1. Tift238D

2. IP10401

3. IP10402

4. IP8214

5. 81B

6. ICMP451

7. LGD-1

8. ICMP85410

9. Tift23DB

10. 843B

11. P7

12. PT732B

13. P1449

14. 841B

15. 863B

16. H77

17. PRLT2

18. ICMP501

19. Tift383

20. 700481-21-8

#### References

1. J. Craig Venter, et al. 2001. Science 291:1304-1315.
2. P. Vos, et al. 1995. Nucleic Acids Res 23:4407-4414.
3. D. Altshuler, et al. 2000. Nature 407: 513-516.
4. Hua Da rice sequence database:  
<http://210.83.138.53/rice/tools.php>
5. Japanese sequence database: <http://rgp.dna.affrc.go.jp/>

#### Table 1 Sequences of enhancing linkers

Acc I

5'-TTGGCGTTTAC-3'

5'-ATGTAAACGCC-3'

5'-CGGTAAACGCC-3'

Aci I

5'-TTGGCGTTTAC-3'

5'-CGGTAAACGCC-3'

Afl III

5'-TTGGCGTTTAC-3'

5'-CUYGGTAAACGCC-3'

Alu I

5'-TTGGCGTTTAC-3'

5'-GTAAACGCC-3'

Apo I

5' -TTGGCGTTTAC-3'

5' -AATTGTAAACGCC-3'

*Ban I*

5' -TTGGCGTTTAC-3'

5 5' -GYUCGTAAACGCC-3'

*Ban II*

5' -TTGGCGTTTACUGCY-3'

5' -GTAAACGCC-3'

*Bfa I*

10 5' -TTGGCGTTTAC-3'

5' -TAGTAAACGCC-3'

*BsaA I*

5' -TTGGCGTTTAC-3'

5' -GTAAACGCC-3'

15 *BsaH I*

5' -TTGGCGTTTAC-3'

5' -CGGTAAACGCC-3'

*BsaJ I*

5' -TTGGCGTTTAC-3'

20 5' -CNNGGTAAACGCC-3'

*BsiE I*

5' -TTGGCGTTTACUY-3'

5' -GTAAACGCC-3'

*BssK I*

25 5' -TTGGCGTTTAC-3'

5' -CCNNGGTAAACGCC-3'

*BstN I*

None is needed.

*BstU I*

30 5' -TTGGCGTTTAC-3'

5' -GTAAACGCC-3'

*Btg I*

5' -TTGGCGTTTAC-3'

5' -CUYGGTAAACGCC-3'

35 *Cac8 I*

5' -TTGGCGTTTAC-3'

5' -GTAAACGCC-3'

*DpnI*

5' -TTGGCGTTTAC-3'

5'-GTAAACGCC-3'

*Dpn II*

5'-TTGGCGTTTAC-3'

5'-GATCGTAAACGCC-3'

5 *Dra I*

5'-TTGGCGTTTAC-3'

5'-AATTGTAAACGCC-3'

*Eae I*

5'-TTGGCGTTTAC-3'

10 5'-GGCCGTAAACGCC-3'

*Fnu4H I*

None is needed.

*Hae II*

5'-TTGGCGTTTACGCGC-3'

15 5'-GTAAACGCC-3'

*Hae III*

5'-TTGGCGTTTAC-3'

5'-GTAAACGCC-3'

*Hha I*

20 5'-TTGGCGTTTACCG-3'

5'-GTAAACGCC-3'

*Hinc II*

5'-TTGGCGTTTAC-3'

5'-GTAAACGCC-3'

25 *Hinf I*

5'-TTGGCGTTTAC-3'

5'-ANTGTAAACGCC-3'

*HinP1 I*

5'-TTGGCGTTTAC-3'

30 5'-CGGTAAACGCC-3'

*Hpa II*

5'-TTGGCGTTTAC-3'

5'-CGGTAAACGCC-3'

*Hpy188 I*

35 None is needed.

*HpyCH4 III*

None is needed.

*HpyCH4 IV*

5'-TTGGCGTTTAC-3'



5' -CGGTAAACGCC-3'

*HpyCH4* V

5' -TTGGCGTTTAC-3'

5' -GTAAACGCC-3'

5 *Mbo* I

5' -TTGGCGTTTAC-3'

5' -GATCGTAAACGCC-3'

*Mnl* I

None is needed.

10 *Mse* I

5' -TTGGCGTTTAC-3'

5' -TAGTAAACGCC-3'

*Msl* I

None is needed.

15 *Msp* I

5' -TTGGCGTTTAC-3'

5' -CGGTAAACGCC-3'

*Nla* III

5' -TTGGCGTTTACCATG-3'

20 5' -GTAAACGCC-3'

*Nla* IV

5' -TTGGCGTTTAC-3'

5' -GTAAACGCC-3'

*Nsp* I

25 5' -TTGGCGTTTACCATG-3'

5' -GTAAACGCC-3'

*Rsa* I

5' -TTGGCGTTTAC-3'

5' -GTAAACGCC-3'

30 *Sau3A* I

5' -TTGGCGTTTAC-3'

5' -GATCGTAAACGCC-3'

*Sau96* I

5' -TTGGCGTTTAC-3'

35 5' -GNCGTAAACGCC-3'

*ScrF* I

None is needed.

*Sfc* I

5' -TTGGCGTTTAC-3'

5' -TUYAGTAAACGCC-3'

*Sml* I

5' -TTGGCGTTTAC-3'

5' -TYUAGTAAACGCC-3'

5 *Taq* I

5' -TTGGCGTTTAC-3'

5' -CGGTAAACGCC-3'

*Tsp509* I

5' -TTGGCGTTTAC-3'

10 5' -AATTGTAAACGCC-3'

*CviJ* I

None is needed.

*CviT* I

None is needed.

15

Table 2 20 Rice Varieties

Series No.	RC No.	IRGC No.	Name
1	1	25833	AusJhari
2	8	25885	Lakhsnikajal
3	10	25898	Mimidim
4	17	27502	Walanga
5	18	27522	Ashmber
6	21	33118	Hnanwa
7	26	34737	Bawoi
8	27	38697	NPE837
9	28	62154	ASU
10	33	64780	Kalshori
11	36	64792	Narikel Jhupi
12	40	64887	Dagpa Bara
13	48	66513	Guru Muthessa
14	50	66529	Podi Niyanwee
15	58	66614	Puteh Kaca
16	81	67423	Aguyod
17	88	67720	Banikat
18	98	71496	Babalatik
19	178	78333	Khau Muong Pieng
20	181	78369	Nep Ngau

PCT Application

**GB0303866**

